These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 18417722)

  • 21. The ubiquitous nature and elusive role of phosphorus and vascular calcification.
    Goldstein-Fuchs J; Fouque D
    Am J Kidney Dis; 2009 Mar; 53(3):363-5. PubMed ID: 19231735
    [No Abstract]   [Full Text] [Related]  

  • 22. Sodium-dependent phosphate cotransporters and vascular calcification.
    Li X; Giachelli CM
    Curr Opin Nephrol Hypertens; 2007 Jul; 16(4):325-8. PubMed ID: 17565274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of phosphorus in the development and progression of vascular calcification.
    Kendrick J; Chonchol M
    Am J Kidney Dis; 2011 Nov; 58(5):826-34. PubMed ID: 21956015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular calcification in patients with chronic kidney disease: types, clinical impact and pathogenesis.
    Román-García P; Rodríguez-García M; Cabezas-Rodríguez I; López-Ongil S; Díaz-López B; Cannata-Andía JB
    Med Princ Pract; 2011; 20(3):203-12. PubMed ID: 21454988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.
    Mehrotra R
    J Ren Nutr; 2006 Apr; 16(2):100-18. PubMed ID: 16567266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Atheroma and vascular calcification in hemodialysis patients].
    Joki N; Tanaka Y
    Clin Calcium; 2010 Jul; 20(7):1061-6. PubMed ID: 20585185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Experimental study of the mechanism for vascular calcification in chronic kidney disease].
    Persy V
    Verh K Acad Geneeskd Belg; 2008; 70(4):285-303. PubMed ID: 19166100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular calcification and arterial stiffness in chronic kidney disease: implications and management.
    Toussaint ND; Kerr PG
    Nephrology (Carlton); 2007 Oct; 12(5):500-9. PubMed ID: 17803475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular calcification in chronic kidney disease.
    Chen NX; Moe SM
    Semin Nephrol; 2004 Jan; 24(1):61-8. PubMed ID: 14730511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
    Williams MJ; Sugatani T; Agapova OA; Fang Y; Gaut JP; Faugere MC; Malluche HH; Hruska KA
    Kidney Int; 2018 Jan; 93(1):147-158. PubMed ID: 28843411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The mechanisms of hyperphosphatemia-induced vascular calcification.
    Cozzolino M; Gallieni M; Brancaccio D
    Int J Artif Organs; 2008 Dec; 31(12):1002-3. PubMed ID: 19115191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Chronic kidney disease (CKD) and bone. Vascular calcification in CKD].
    Yokoyama K
    Clin Calcium; 2009 Apr; 19(4):552-8. PubMed ID: 19329835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients.
    Cozzolino M; Brancaccio D
    Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):29-34. PubMed ID: 18221100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
    Koizumi M; Fukagawa M
    Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD).
    Moe SM; Reslerova M; Ketteler M; O'neill K; Duan D; Koczman J; Westenfeld R; Jahnen-Dechent W; Chen NX
    Kidney Int; 2005 Jun; 67(6):2295-304. PubMed ID: 15882271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperphosphatemia and vascular calcification in end-stage renal disease.
    Nishizawa Y; Jono S; Ishimura E; Shioi A
    J Ren Nutr; 2005 Jan; 15(1):178-82. PubMed ID: 15648030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apelin: A novel inhibitor of vascular calcification in chronic kidney disease.
    Han X; Wang LY; Diao ZL; Liu WH
    Atherosclerosis; 2016 Jan; 244():1-8. PubMed ID: 26581047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular calcification in uremic conditions: new insights into pathogenesis.
    Cozzolino M; Gallieni M; Brancaccio D
    Semin Nephrol; 2006 Jan; 26(1):33-7. PubMed ID: 16412823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.